All sponsors

AstraZeneca $AZN

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS289
PHASE 3 / 2-3175
RECRUITING124
READOUTS ≤12 MONTHS58
READOUT SLIPPED >6 MO49%

Delay Index: of 226 active trials registered more than a year ago, 110 have moved their primary completion (readout) date by more than 6 months since first registration (median +5.4 months). See all sponsors →

Open AstraZeneca on the live radar map → 📅 $AZN readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
CONFIRM
NCT00099437
P3Active, not recruitingBreast Cancer7362009-02-27
olaparib
NCT01081951
P2Active, not recruitingOvarian Cancer1622011-10-10 (+1 mo)
SELECT-1
NCT01933932
P3Active, not recruitingLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV5102016-06-07
Olaparib 300mg tablets
NCT01874353
P3Active, not recruitingPlatinum Sensitive; BRCA Mutated3272016-09-19 (+15 mo)
SOLO-1
NCT01844986
P3Active, not recruitingNewly Diagnosed; Advanced Ovarian Cancer4502018-05-17 (+23 mo)
MYSTIC
NCT02453282
P3Active, not recruitingNon-Small-Cell Lung Carcinoma NSCLC11182018-10-04 (+17 mo)
Savolitinib
NCT03091192
P3Active, not recruitingCarcinoma; Carcinoma, Renal Cell602019-08-18 (-18 mo)
CASPIAN
NCT03043872
P3Active, not recruitingSmall Cell Lung Carcinoma Extensive Disease9872020-01-27
MEDI4736 (Durvalumab)
NCT02516241
P3Active, not recruitingUrothelial Cancer11262020-01-27 (+27 mo)
OlympiA
NCT02032823
P3Active, not recruitingBreast Cancer18372020-03-27
NEPTUNE
NCT02542293
P3Active, not recruitingNon Small Cell Lung Carcinoma NSCLC9532020-09-21 (+26 mo)
BAYOU
NCT03459846
P2Active, not recruitingUrinary Bladder Neoplasms1542020-10-15 (+13 mo)
Olaparib Continuous (28-Day cycle) 300 mg BD.
NCT03330847
P2Active, not recruitingMetastatic Triple Negative Breast Cancer2732020-11-13 (+1 mo)
ORION
NCT03775486
P2Active, not recruitingNon-small Cell Lung Cancer NSCLC4012021-01-11 (+4 mo)
POSEIDON
NCT03164616
P3Active, not recruitingNon Small Cell Lung Cancer NSCLC11862021-03-12 (+19 mo)
olaparib
NCT03732820
P3Active, not recruitingMetastatic Castration-resistant Prostate Cancer8952021-07-30 (+4 mo)
TOPAZ-1
NCT03875235
P3Active, not recruitingBiliary Tract Neoplasms8102021-08-11 (-7 mo)
HIMALAYA
NCT03298451
P3Active, not recruitingHepatocellular Carcinoma13242021-08-27 (+18 mo)
MEDIOLA
NCT02734004
P1/2Active, not recruitingOvarian; Breast2642021-09-17 (+27 mo)
ADAURA
NCT02511106
P3Active, not recruitingStage IB-IIIA Non-small Cell Lung Carcinoma6822022-04-11 (+9 mo)
INTERLINK-1
NCT04590963
P3Active, not recruitingSquamous Cell Carcinoma of the Head and Neck3702022-05-11 (-23 mo)
TAZMAN
NCT04745689
P2Active, not recruitingSmall-Cell Lung Cancer312022-06-18 (-14 mo)
SERENA-2
NCT04214288
P2Active, not recruitingAdvanced ER-Positive HER2-Negative Breast Cancer2402022-08-30 (+5 mo)
Durvalumab (MEDI4736)
NCT03003962
P3Active, not recruitingNon Small Cell Lung Carcinoma NSCLC6692022-10-27 (+28 mo)
AEGEAN
NCT03800134
P3Active, not recruitingNon-Small Cell Lung Cancer8252022-11-10 (+27 mo)
CoC
NCT04606771
P2Active, not recruitingNon-Small Cell Lung Cancer302022-12-21 (+7 mo)
Acalabrutinib
NCT03932331
P1/2Active, not recruitingPhase I: Relapsed or Refractory B-cell Malignancies; Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma1052022-12-22 (+27 mo)
DPT01
NCT04639219
P2Active, not recruitingAdvanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast1022023-01-25 (+3 mo)
Durvalumab / Tremelimumab Combination Therapy
NCT03837899
P1/2Active, not recruitingPediatric Cancer; Solid Tumor Pediatric502023-02-28 (+17 mo)
FLAURA2
NCT04035486
P3Active, not recruitingNon-Small Cell Lung Cancer5872023-04-03
CAPItello-291
NCT04305496
P3Active, not recruitingLocally Advanced (Inoperable) or Metastatic Breast Cancer8182023-05-09 (+5 mo)
MANDARA
NCT04157348
P3Active, not recruitingEosinophilic Granulomatous Vasculitis1402023-08-10 (+13 mo)
EMERALD-1
NCT03778957
P3Active, not recruitingHepatocellular Carcinoma7242023-09-11 (+29 mo)
Datopotamab Deruxtecan (Dato-DXd)
NCT05460273
P1/2Active, not recruitingCarcinoma, Non-Small-Cell Lung; Triple Negative Breast Cancer1192023-11-07 (-1 mo)
Acalabrutinib
NCT04075292
P3Active, not recruitingUntreated Chronic Lymphocytic Leukemia1552024-01-03 (+10 mo)
LAURA
NCT03521154
P3Active, not recruitingNon Small Cell Lung Cancer (Stage III)2162024-01-05 (+26 mo)
ADRIATIC
NCT03703297
P3Active, not recruitingSmall Cell Lung Cancer7302024-01-15 (+31 mo)
olaparib
NCT05171816
P3Active, not recruitingMetastatic Castration-resistant Prostate Cancer1102024-01-22 (-2 mo)
DESTINY-B12
NCT04739761
P3Active, not recruitingBreast Cancer5062024-02-08 (-3 mo)
DB-06
NCT04494425
P3Active, not recruitingAdvanced or Metastatic Breast Cancer8662024-03-18 (+15 mo)
MONETTE
NCT05061134
P2Active, not recruitingMelanoma1942024-04-12 (+4 mo)
NIAGARA
NCT03732677
P3Active, not recruitingMuscle Invasive Bladder Cancer10632024-04-29 (-20 mo)
PACIFIC-5
NCT03706690
P3Active, not recruitingCarcinoma, Non-Small-Cell Lung4072024-06-23 (+39 mo)
DUO-E
NCT04269200
P3Active, not recruitingEndometrial Neoplasms8052024-07-08 (+13 mo)
Dato-DXd
NCT05104866
P3Active, not recruitingBreast Cancer7322024-07-24 (+12 mo)
LOTOS
NCT05941897
P2Active, not recruitingAdvanced or Metastatic NSCLC392024-07-29
KOMET
NCT04924608
P3Active, not recruitingNeurofibromatosis 1; Plexiform Neurofibroma (PN)1452024-08-05 (+8 mo)
SAVANNAH
NCT03778229
P2Active, not recruitingCarcinoma3672024-08-23 (+43 mo)
HUDSON
NCT03334617
P2Active, not recruitingNon-Small Cell Lung Cancer5282024-09-13 (+50 mo)
AZD0171
NCT04999969
P2Active, not recruitingLocally Advanced or Metastatic Solid Tumours1262024-10-07 (+10 mo)
CAPItello-281
NCT04493853
P3Active, not recruitingHormone-Sensitive Prostate Cancer10122024-10-07 (+8 mo)
NeoADAURA
NCT04351555
P3Active, not recruitingNon-Small Cell Lung Cancer3582024-10-15 (+9 mo)
COMPEL
NCT04765059
P3Active, not recruitingNon-small Cell Lung Cancer982024-10-28 (+3 mo)
DL-05
NCT05246514
P2Active, not recruitingHER2-mutant Non-Small Cell Lung Cancer722024-11-04 (+11 mo)
BEGONIA
NCT03742102
P1/2Active, not recruitingTriple Negative Breast Neoplasms2432024-11-29 (+49 mo)
AZD7789
NCT04931654
P1/2Active, not recruitingCarcinoma, Non-Small-Cell Lung; Gastric Cancer1362024-12-04 (-5 mo)
Durvalumab
NCT04592913
P3Active, not recruitingGastrointestinal Neoplasms; Esophagogastric Junction9572024-12-20 (-2 mo)
DB-07
NCT04538742
P1/2Active, not recruitingMetastatic Breast Cancer2452025-01-31 (+14 mo)
Trastuzumab Deruxtecan
NCT05113251
P3Active, not recruitingBreast Neoplasms; Breast Cancer9272025-03-12 (+13 mo)
DUO-O
NCT03737643
P3Active, not recruitingAdvanced Ovarian Cancer14072025-03-17 (+34 mo)
POTOMAC
NCT03528694
P3Active, not recruitingNon-muscle-invasive Bladder Cancer10182025-04-03 (+40 mo)
ORCHARD
NCT03944772
P2Active, not recruitingNon-Small Cell Lung Cancer2472025-05-06
NATRON
NCT04191304
P3Active, not recruitingHypereosinophilic Syndrome1342025-05-07 (+34 mo)
PATAPSCO
NCT05943106
P3Active, not recruitingNon-Muscle- Invasive Bladder Cancer1002025-06-16 (-25 mo)
SERENA-6
NCT04964934
P3Active, not recruitingER-Positive HER2-Negative Breast Cancer3152025-06-30 (+21 mo)
Tulip SC
NCT04877691
P3Active, not recruitingSystemic Lupus Erythematosus3672025-08-22 (+17 mo)
Dato-DXd
NCT05374512
P3Active, not recruitingBreast Cancer6442025-08-25 (-3 mo)
TOURMALINE
NCT05771480
P3Active, not recruitingBiliary Tract Cancer1422025-10-02 (-6 mo)
LATIFY
NCT05450692
P3Active, not recruitingAdvanced or Metastatic Non-Small Cell Lung Cancer5942025-10-06 (+4 mo)
SAMETA
NCT05043090
P3Active, not recruitingPapillary Renal Cell Carcinoma1482025-12-31 (+22 mo)
MDT-BRIDGE
NCT05925530
P2Active, not recruitingNon-small Cell Lung Cancer1422026-01-12 (-3 mo)
PANDA
NCT07128615
P1/2Active, not recruitingInfluenza A4052026-01-28
EMERALD-3
NCT05301842
P3Active, not recruitingHepatocellular Carcinoma7602026-02-23 (+4 mo)
VOLGA
NCT04960709
P3Active, not recruitingMuscle Invasive Bladder Cancer7122026-03-02 (+7 mo)
CAPItello280
NCT05348577
P3Active, not recruitingProstate Cancer10352026-03-04 (-5 mo)
CAPItello-290
NCT03997123
P3Active, not recruitingTriple Negative Breast Neoplasms9232026-03-16 (+54 mo)
SIERRA
NCT05883644
P3Active, not recruitingAdvanced Hepatocellular Carcinoma1112026-03-30
AMALTHEA
NCT06450197
P2Active, not recruitingModerate to Severe Crohn's Disease1202026-04-30
LADOGA
NCT06606847
P2Active, not recruitingNon-Small Cell Lung Cancer302026-05-04 (-2 mo)
EPIC-ATTR
NCT06194825
P3Active, not recruitingTransthyretin Amyloid Cardiomyopathy642026-05-13 (+14 mo)
AZD0901
NCT06346392
P3Active, not recruitingGastric Cancer; Gastroesophageal Junction Cancer5942026-05-31 (+2 mo)
NILE
NCT03682068
P3Active, not recruitingUnresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer12462026-06-01 (+49 mo)
Trastuzumab Deruxtecan
NCT05048797
P3Active, not recruitingLocally Advanced or Metastatic Non-Small Cell Lung Cancer4542026-06-09 (+17 mo)
SERENA-4
NCT04711252
P3Active, not recruitingER-Positive HER2-Negative Breast Cancer13712026-06-26 (+8 mo)
EMERALD-Y90
NCT06040099
P2Active, not recruitingHepatocellular Carcinoma (HCC)582026-06-30 (-3 mo)
SAFFRON
NCT05261399
P3Active, not recruitingCarcinoma; Non-Small-Cell Lung3412026-07-06 (+13 mo)
NEOLA
NCT06194448
P2Active, not recruitingLung Cancer762026-07-07 (-8 mo)
TROPION-Lung12
NCT06564844
P3Active, not recruitingNon-small Cell Lung Cancer252026-07-10 (-64 mo)
CROSSING
NCT05583227
P3Active, not recruitingEosinophilic Esophagitis3682026-07-14 (+2 mo)
MONO-OLA1
NCT04884360
P3Active, not recruitingOvarian Cancer3662026-07-27 (+26 mo)
PACIFIC-8
NCT05211895
P3Active, not recruitingNon-Small Cell Lung Cancer7912026-08-10 (+5 mo)
CALLISTO
NCT06681324
P2Active, not recruitingCrohn's Disease242026-08-10 (+7 mo)
GAMBIT
NCT07143604
P2Active, not recruitingGastric Cancer; Gastroesophageal Junction Cancer332026-08-14 (-1 mo)
eVOLVE-Lung02
NCT05984277
P3Active, not recruitingMetastatic Non-small Cell Lung Cancer8952026-08-17 (-21 mo)
ZODIAC
NCT06942910
P2Active, not recruitingChronic Kidney Disease With High Proteinuria2242026-09-26 (+2 mo)
TREMENDOUS
NCT05557838
P3Active, not recruitingHepatocellular Carcinoma2142026-09-30 (+18 mo)
ARIES
NCT07717840
P1/2Active, not recruitingRSV Respiratory Syncytial Virus1642026-10-01
AZD6234
NCT07017179
P2Active, not recruitingObesity/Overweight162026-10-23 (+3 mo)
Volrustomig
NCT05775159
P2Active, not recruitingHepatocellular Carcinoma; Biliary Tract Cancer2942026-10-27 (+24 mo)
TRITON
NCT06008093
P2Active, not recruitingCarcinoma, Non-Small-Cell Lung1032026-10-27 (-1 mo)
CAPItrue
NCT06635447
P3Active, not recruitingBreast Cancer2932026-10-31 (+6 mo)
LAVENDER
NCT06015737
P3Active, not recruitingCutaneous Lupus Erythematosus3392026-11-02 (+7 mo)
ANDROMEDA
NCT07336446
P1/2Active, not recruitingProstate Cancer62026-11-05
AZD0901
NCT06219941
P2RecruitingGastric Cancer; Gastroesophageal Junction Cancer2262026-11-17 (+20 mo)
APOLLO
NCT06267729
P1/2RecruitingMetastatic Prostate Cancer602026-11-24 (-5 mo)
TREMENDOUS-2
NCT07081633
P2Active, not recruitingHepatocellular Carcinoma1142026-11-30
BaxDuo-Baltic
NCT07222917
P2Active, not recruitingChronic Kidney Disease and Hypertension2222026-12-10 (-5 mo)
DOMINICA
NCT05692180
P3Active, not recruitingAsthma942026-12-23 (-40 mo)
ROSY-D
NCT05303532
P3Enrolling by invitationCancer2142026-12-31 (+26 mo)
AZURE-HeFH
NCT07000136
P3Active, not recruitingHeterozygous Familial Hypercholesterolaemia4732027-01-04 (-3 mo)
DAISY
NCT05925803
P3Active, not recruitingSystemic Sclerosis; Scleroderma3142027-01-06 (-12 mo)
PACIFIC-9
NCT05221840
P3Active, not recruitingNon-Small Cell Lung Cancer10512027-01-08 (+7 mo)
TROPION-Lung15
NCT06417814
P3Active, not recruitingMetastatic Non-small Cell Lung Cancer7682027-01-11 (+4 mo)
AZURE-LDL
NCT07000123
P3Active, not recruitingCardiovascular Disease31032027-01-11 (-2 mo)
ESSENCE
NCT06706817
P3Active, not recruitingChronic Rhinosinusitis With Nasal Polyps1812027-01-13
SOUND
NCT05374603
P2Active, not recruitingLung Cancer472027-01-18 (+39 mo)
CONTEMPO
NCT06151964
P1/2Active, not recruitingOverweight and Obesity1662027-01-29 (+25 mo)
Trastuzumab deruxtecan
NCT06271837
P2Active, not recruitingAdvanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)1272027-02-10 (+15 mo)
SERENIA
NCT07215702
P2RecruitingSepsis; Acute Kidney Injury1242027-02-11
Zibotentan/Dapagliflozin
NCT06087835
P3Active, not recruitingChronic Kidney Disease With High Proteinuria18352027-02-18 (-5 mo)
Rosuvastatin Dose 1
NCT06834932
P2/3Active, not recruitingDyslipidaemia4322027-02-22 (+20 mo)
ROSY-T
NCT05629234
P3Active, not recruitingCancer372027-02-22 (+11 mo)
IRIS
NCT05138133
P3Active, not recruitingLupus Nephritis3632027-02-23 (+16 mo)
PEAK
NCT06749457
P1/2Active, not recruitingStaphylococcus Aureus2422027-03-08 (+5 mo)
DPT02
NCT04482309
P2Active, not recruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer; Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer4772027-03-23 (+48 mo)
AZD4360
NCT06921928
P1/2Active, not recruitingGastric Cancer; Gastroesophageal Junction Cancer312027-03-31 (-4 mo)
ROSY-O
NCT04421963
P3Active, not recruitingOvarian Cancer; Breast Cancer1852027-04-06 (+24 mo)
BalanceD-HF
NCT06307652
P3RecruitingHeart Failure and Impaired Kidney Function38502027-04-16 (-2 mo)
PRISM
NCT07285213
P2RecruitingClostridioides Difficile Infection2302027-04-20
CAMBRIA-1
NCT05774951
P3RecruitingBreast Cancer, Early Breast Cancer43002027-04-20
Trastuzumab deruxtecan
NCT04784715
P3Active, not recruitingBreast Cancer; HER2-positive; Metastatic11572027-05-03 (+21 mo)
DG-03
NCT04379596
P2Active, not recruitingGastric Cancer4522027-05-04 (+52 mo)
PETRA
NCT04644068
P1/2Active, not recruitingOvarian Cancer; Breast Cancer7022027-05-28 (+22 mo)
laroprovstat/rosuvastatin 1
NCT07619118
P3RecruitingHypercholesterolaemia2002027-05-28
Umbriel
NCT06932263
P2RecruitingAsthma5402027-06-07 (-1 mo)
ARRIVAL
NCT06473779
P3Active, not recruitingSevere Asthma3102027-06-25
KUNLUN
NCT04550260
P3Active, not recruitingEsophageal Squamous Cell Carcinoma6402027-06-30 (+24 mo)
RHEA-1
NCT06795022
P1/2RecruitingHepatocellular Carcinoma3042027-06-30 (-7 mo)
CANTOR
NCT06792695
P2Active, not recruitingMetastatic Colorectal Cancer822027-06-30 (+3 mo)
CYCAD-1
NCT06188520
P1/2Active, not recruitingER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC)552027-06-30 (+24 mo)
BRAVO
NCT07610837
P2RecruitingLiver Fibrosis; Hepatic Cirrhosis1042027-07-07
MAJIC
NCT05057494
P3Active, not recruitingChronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma6072027-07-15 (-15 mo)
BaxPA
NCT07007793
P3Active, not recruitingPrimary Hyperaldosteronism2122027-07-27 (-7 mo)
Dato-DXd
NCT06103864
P3RecruitingBreast Cancer6252027-07-28 (+10 mo)
Laroprovstat
NCT07619131
P3RecruitingHypercholesterolaemia6002027-07-30
eVOLVE-01
NCT06448754
P2Active, not recruitingNon-small Cell Lung Cancer1942027-07-30 (+23 mo)
ADAURA2
NCT05120349
P3Active, not recruitingNon-Small Cell Lung Cancer3902027-08-02
PRESTO
NCT07082738
P2RecruitingChronic Obstructive Pulmonary Disease (COPD)9872027-08-31 (-2 mo)
Dato-DXd
NCT05629585
P3Active, not recruitingBreast Cancer11742027-09-01
AZD8205
NCT05123482
P1/2RecruitingBreast Cancer; Biliary Tract Carcinoma4602027-09-29 (+28 mo)
EvoPAR-PR01
NCT06120491
P3Active, not recruitingMetastatic Castration-Sensitive Prostate Cancer18982027-09-30 (-3 mo)
OSTARA
NCT05801029
P2Active, not recruitingNon-Small Cell Lung Cancer (NSCLC)602027-10-01
Datopotamab deruxtecan (Dato-DXd)
NCT05489211
P2RecruitingEndometrial Cancer; Gastric Cancer4542027-10-01 (+28 mo)
DURGA-1
NCT05850234
P1/2RecruitingRelapsed/Refractory Multiple Myeloma2322027-10-01 (+19 mo)
APPRECIATE
NCT06824987
P2Active, not recruitingAPOL1-Mediated Kidney Disease632027-10-04
BAIYUN
NCT06471257
P3RecruitingAsthma10002027-10-04 (+11 mo)
Laroprovstat
NCT07930507
P3Not yet recruitingHypercholesterolemia2042027-10-11
ACADIA
NCT06307665
P3RecruitingAsthma4402027-10-13
Puxitatug Samrotecan
NCT07044336
P3RecruitingEndometrial Cancer; Malignant Solid Tumour8002027-10-15
CAPItello-292
NCT04862663
P3Active, not recruitingLocally Advanced (Inoperable) or Metastatic Breast Cancer8932027-11-01 (+36 mo)
AVANZAR
NCT05687266
P3Active, not recruitingNSCLC13502027-11-01 (+5 mo)
TILIA
NCT05624450
P3RecruitingViral Lung Infection and Acute Respiratory Failure35272027-11-04 (+42 mo)
Sonesitatug Vedotin
NCT07069712
P2RecruitingGastroesophageal Adenocarcinoma1002027-11-09 (+11 mo)
LaunchPAD-RA
NCT07276581
P2RecruitingRheumatoid Arthritis3202027-11-12
CRIUS-1
NCT07529717
P1/2RecruitingMetastatic Prostate Cancer422027-11-17
eVOLVECervical
NCT06079671
P3RecruitingLocally Advanced Cervical Cancer8002027-11-26 (+9 mo)
Rilvegostomig
NCT05702229
P2RecruitingGastric Cancer1632027-11-30 (+41 mo)
SPRINKLE
NCT05309668
P1/2Active, not recruitingNeurofibromatosis Type 1362027-11-30 (+49 mo)
CAPItana
NCT06764186
P3Active, not recruitingLocally Advanced or Metastatic Breast Cancer1012027-11-30 (-1 mo)
THARROS
NCT06283966
P3RecruitingCOPD (Chronic Obstructive Pulmonary Disease)52502027-12-03 (-3 mo)
CLEAR
NCT07088926
P2RecruitingBronchiectasis With Pseudomonas Aeruginosa Colonization4352027-12-09
ATHENA
NCT06084884
P1/2Active, not recruitingHepatocellular Carcinoma942027-12-13
SERENA-1b
NCT07427394
P2RecruitingAdvanced Breast Cancer242027-12-28
SOUND-MCL
NCT07029737
P2RecruitingMantle-cell Lymphoma552027-12-31 (+7 mo)
SYRUS
NCT06137118
P1/2RecruitingB-cell Acute Lymphoblastic Leukemia (B-ALL)2552028-01-06 (+23 mo)
JASMINE
NCT06455449
P3RecruitingPolymyositis, Dermatomyositis2402028-01-10 (+8 mo)
BREEZE
NCT07774403
P2RecruitingBronchiectasis With Pseudomonas Aeruginosa Colonization842028-01-18
AZD0305
NCT06106945
P1/2RecruitingMultiple Myeloma2262028-01-24 (+27 mo)
TB06
NCT07205822
P3RecruitingBreast Cancer1002028-02-02
TAPER
NCT07363642
P3RecruitingSevere Asthma4002028-02-07
CERTIS1
NCT05417594
P1/2RecruitingAdvanced Solid Malignancies6952028-02-07 (+46 mo)
BaxNoD
NCT07686120
P3RecruitingUncontrolled Hypertension2862028-02-09
CLIPS
NCT06512883
P3RecruitingEosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilia Syndrome (HES)142028-02-20 (+14 mo)
AURORA
NCT07295847
P1/2RecruitingSystemic Sclerosis; Idiopathic Inflammatory Myopathies272028-02-22
Baxdrostat/dapagliflozin
NCT06268873
P3Active, not recruitingChronic Kidney Disease and Hypertension25542028-02-24 (+2 mo)
BIFANG
NCT07520162
P3RecruitingChronic Rhinosinusitis With Nasal Polyps2302028-03-01
IVOLGA
NCT06943833
P2Active, not recruitingLocally Advanced Cervical Cancer372028-03-13
TROPION-Lung14
NCT06350097
P3RecruitingNon-small Cell Lung Cancer5822028-03-21
Elecoglipron
NCT07775404
P3RecruitingObesity; Overweight3512028-04-06
SOUNDTRACK-B
NCT06526793
P2RecruitingB-cell Non-Hodgkin Lymphoma; Follicular Lymphoma (FL)2702028-04-21 (+14 mo)
Eluminate-2
NCT07662213
P3RecruitingType 2 Diabetes Mellitus12002028-05-23
Eluminate-3
NCT07664553
P3RecruitingType 2 Diabetes Mellitus6002028-05-23
HORIZON
NCT06023589
P3RecruitingAsthma2312028-05-31 (+13 mo)
ARTEMIDE-01
NCT04995523
P1/2Active, not recruitingNon-Small-Cell Lung Carcinoma2122028-06-01 (+55 mo)
DESTINY-BTC01
NCT06467357
P3RecruitingBiliary Tract Cancer6202028-06-12 (+2 mo)
DURGA-4
NCT07391657
P3RecruitingRelapsed Refractory Multiple Myeloma5082028-06-14
Lumi-NHL
NCT07123454
P1/2RecruitingB-cell Non-Hodgkin Lymphoma1642028-07-04 (+4 mo)
Eluminate-5
NCT07662109
P3RecruitingType 2 Diabetes Mellitus20002028-07-05
Eluminate-4
NCT07662135
P3RecruitingType 2 Diabetes Mellitus; Type 2 Diabetes With Chronic Kidney Disease9002028-07-13
Eluminate-1
NCT07662044
P3RecruitingType 2 Diabetes Mellitus8002028-07-14
Embold
NCT07667803
P3RecruitingWeight Management45002028-07-31
FONTANA
NCT05797168
P1/2RecruitingOvarian Cancer; Lung Adenocarcinoma6222028-08-04 (+10 mo)
SELENE 2
NCT07784270
P3RecruitingObesity or Overweight; Diabetes Mellitus, Type 215002028-08-09
SELENE 3
NCT07776509
P3RecruitingObesity or Overweight; Weight-Related Comorbidity5002028-08-09
SELENE 1
NCT07784725
P3RecruitingObesity or Overweight25002028-08-11
LOTUS
NCT07751848
P3RecruitingLupus Erythematosus, Systemic4172028-08-25
Durvalumab
NCT06960577
P2RecruitingUrinary Bladder Neoplasms; Immune Checkpoint Inhibitors1502028-08-30 (-2 mo)
SELENE-Asia
NCT07922330
P3Not yet recruitingObesity; Overweight3302028-09-15
ARGiNAUT
NCT07652658
P2RecruitingIdiopathic Pulmonary Fibrosis (IPF)3592028-09-18
TREVI-OC-03
NCT07816666
P3RecruitingPlatinum-sensitive Relapsed Epithelial Ovarian Cancer; Platinum-sensitive Relapsed Fallopian Tube Cancer6002028-09-29
BLOSSOM
NCT05835310
P3RecruitingSystemic Lupus Erythematosus1002028-10-05 (-12 mo)
ALLight
NCT07109219
P1/2RecruitingB-cell Acute Lymphoblastic Leukemia (B-ALL)832028-10-11 (+5 mo)
CLEAR-AbKD
NCT07571746
P2RecruitingPrimary Membranous Nephropathy432028-10-13
PACIFIC-4
NCT03833154
P3Active, not recruitingCarcinoma, Non-Small-Cell Lung7242028-10-31 (+61 mo)
TrAVeRse
NCT05951959
P2Active, not recruitingMantle Cell Lymphoma (MCL)1082028-10-31 (+5 mo)
DURGA-6
NCT07735637
P3RecruitingNewly Diagnosed Multiple Myeloma (NDMM)7502028-11-02
eVOLVE-Meso
NCT06097728
P3Active, not recruitingUnresectable Pleural Mesothelioma8632028-11-16 (+19 mo)
TREVI-OC-01
NCT07218809
P3RecruitingEpithelial Ovarian Cancer11002028-11-17
Dato-DXd
NCT06112379
P3Active, not recruitingBreast Cancer19022028-11-20 (+8 mo)
DUoENDE
NCT06746116
P3Active, not recruitingAdvanced or Recurrent Endometrial Cancer452028-11-30
eVOLVE-02
NCT06535607
P2RecruitingSub-study 1 Cervical Cancer (Volrustomig Monotherapy); Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)2572028-11-30 (+27 mo)
PRIMROSE
NCT06130553
P1/2RecruitingAdvanced Solid Tumors That Are MTAP Deficient3342028-12-04 (+33 mo)
PATAGONIA
NCT07941609
P2Not yet recruitingNon-small Cell Lung Cancer (NSCLC)2502028-12-16
ROMEO
NCT07566195
P3RecruitingChronic Obstructive Pulmonary Disease; COPD592028-12-29
Rilvegostomig
NCT06109779
P3Active, not recruitingBiliary Tract Cancer7602029-01-02 (-6 mo)
DURGA-5
NCT07764978
P3RecruitingNewly Diagnosed Multiple Myeloma7502029-01-11
SEACLIFF
NCT07181161
P1/2RecruitingMetastatic Prostate Cancer2832029-01-18
DE-01
NCT06989112
P3RecruitingEndometrial Cancer6002029-01-19
SUNFLOWER
NCT07430306
P3RecruitingSystemic Lupus Erythematosus2452029-01-26
TROPION-Lung17
NCT07291037
P3RecruitingNon-small Cell Lung Cancer (NSCLC)4002029-01-29
ATTRiumph
NCT07608354
P2Active, not recruitingTransthyretin Amyloid Cardiomyopathy (ATTR-CM)3262029-02-06
MOMENTUM
NCT07155226
P1/2RecruitingAcute Lymphoblastic Leukaemia; Acute Myeloid Leukaemia852029-02-15 (-4 mo)
ALTAIR
NCT06996782
P1/2RecruitingAdvanced or Metastatic Non-small Cell Lung Cancer1522029-02-23 (+2 mo)
SERAFA-1
NCT07647328
P3RecruitingER-Positive HER2-Negative Breast Cancer1502029-02-28
JOURNEY
NCT06878261
P3RecruitingChronic Obstructive Pulmonary Disease (COPD)9902029-03-13
EMBARK
NCT06883305
P3RecruitingChronic Obstructive Pulmonary Disease (COPD)9902029-03-13
AZD5863
NCT06005493
P1/2RecruitingGastric Cancer; Gastro-esophageal Junction Cancer3922029-03-16 (+27 mo)
ACTIVATED-4-PC
NCT07192614
P1/2RecruitingProstate Cancer522029-03-29
LIBRA
NCT07098338
P2RecruitingNon-Small Cell Lung Cancer2782029-04-06 (+31 mo)
ACRUE
NCT05952024
P2RecruitingDiffuse Large B-Cell Lymphoma802029-04-22 (+23 mo)
Rilvegostomig
NCT06764875
P3RecruitingHER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma8402029-04-27
MAVRiC
NCT07024706
P2RecruitingChronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)802029-05-01 (-43 mo)
AZD0120
NCT06897930
P1/2RecruitingLupus Erythematosus, Systemic1502029-05-01
PRIMAVERA
NCT06137144
P1/2RecruitingLymphoma; Non-Hodgkin Lymphoma1612029-05-03 (+38 mo)
FAROS
NCT07525375
P2RecruitingAsthma692029-05-23
NSCLC
NCT07295821
P2RecruitingLung Cancer602029-05-30
VECTRA-01
NCT07611110
P3RecruitingMetastatic Castration-resistant Prostate Cancer6702029-06-04
ALBORAN
NCT06992609
P3Active, not recruitingSmall Cell Lung Carcinoma712029-06-30
Osimertinib
NCT05546866
P2Active, not recruitingNon-small Cell Lung Cancer512029-06-30
SOLAIR
NCT07934420
P3Not yet recruitingAsthma2162029-07-30
AB02
NCT07221253
P3RecruitingBiliary Tract Cancer11002029-07-31
Sonesitatug vedotin
NCT07431281
P3RecruitingGastric Cancer; Gastroesophageal Junction Adenocarcinoma21302029-08-16
Elevate-HF
NCT07761117
P3RecruitingHeart Failure With Preserved Ejection Fraction (HFpEF); Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)69502029-09-03
PROSPECTOR
NCT07590934
P1/2RecruitingMetastatic Prostate Cancer1522029-09-25
AZD6750
NCT07115043
P1/2RecruitingMelanoma; Non-small Cell Lung Cancer1202029-10-02 (+6 mo)
CT204V
NCT07932496
P1/2Not yet recruitingRelapsed or Refractory B-Cell Malignancies1602029-10-15
AZURE-Outcomes
NCT07000357
P3RecruitingCardiovascular Disease151002029-10-26
FLOT Chemotherapy
NCT07877818
P3RecruitingGastric; Esophagogastric Junction1402029-11-01
TARGET
NCT05526755
P2Active, not recruitingStage II-IIIB Non-small Cell Lung Carcinoma1882029-11-22 (+5 mo)
Prevent-HF
NCT06677060
P3RecruitingHeart Failure113002029-12-17
TITANium
NCT06542250
P1/2RecruitingB-cell Malignancies1742029-12-18 (+22 mo)
BaxDuo-Pacific
NCT06742723
P3RecruitingChronic Kidney Disease and Hypertension50002029-12-18 (-4 mo)
EvoPAR-BR01
NCT06380751
P3RecruitingAdvanced Breast Cancer7882029-12-18 (+9 mo)
ROSY-F
NCT07444567
P3RecruitingAsthma; Eosinophilic Granulomatosis With Polyangiitis (EGPA)2302029-12-27
TROPION-Lung10
NCT06357533
P3RecruitingNon-Small Cell Lung Cancer6752029-12-28 (-5 mo)
ARTEMIDELung04
NCT06868277
P3RecruitingCarcinoma, Non-Small Cell Lung8302030-01-17
PEDZ-K
NCT03813407
P3RecruitingHyperkalaemia1402030-02-21 (+109 mo)
CAMBRIA-2
NCT05952557
P3Active, not recruitingBreast Cancer, Early Breast Cancer55112030-03-04 (+1 mo)
ARTEMIDE-HCC01
NCT06921785
P3RecruitingHepatocellular Carcinoma12202030-03-15 (+12 mo)
PARTHENON
NCT07446855
P1/2RecruitingSolid Tumours1802030-03-29
eVOLVE-HNSCC
NCT06129864
P3RecruitingLocally Advanced Head and Neck Squamous Cell Carcinoma11452030-04-17 (+15 mo)
Soundtrack-E
NCT06564038
P1/2RecruitingChronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma4082030-05-20 (-8 mo)
NeoCOAST-2
NCT05061550
P2RecruitingNon-small Cell Lung Cancer6302030-05-28 (+63 mo)
SOUNDTRACK-D2
NCT07215585
P3RecruitingLarge B-cell Lymphoma4202030-06-10
TREVI-OC-02
NCT07851025
P3RecruitingEpithelial Ovarian Cancer9502030-06-28
Balcinrenone/dapagliflozin
NCT07624305
P3RecruitingRenal Insufficiency, Chronic28002030-07-01
Rilvegostomig
NCT06692738
P3RecruitingNon-small Cell Lung Cancer11602030-07-01 (+17 mo)
Anifrolumab + APFS
NCT07630714
P2RecruitingSystemic Lupus Erythematosus242030-09-02
Soundtrack D3
NCT07911553
P3Not yet recruitingLarge B-cell Lymphoma12002030-09-02
TU-04
NCT07720284
P3RecruitingHigh-risk Muscle Invasive Urothelial Carcinoma9152030-09-11
Elevate-CKD
NCT07753993
P3RecruitingChronic Kidney Disease70002030-10-04
Rilvegostomig
NCT06627647
P3RecruitingNon-squamous Non-small Cell Lung Cancer11602030-11-18 (+18 mo)
AZD4045
NCT07681596
P1/2RecruitingRelapsed or Refractory Multiple Myeloma1012031-03-06
PETRANHA
NCT05367440
P1/2Active, not recruitingMetastatic Prostate Cancer1742031-04-11 (+87 mo)
EvoPAR-PR05
NCT07711002
P3RecruitingMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)13302031-05-30
SOUNDTRACK-C1
NCT07509151
P3RecruitingChronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV4202031-08-29
Surovatamig
NCT06549595
P3RecruitingUntreated Follicular Lymphoma10182031-11-26 (+7 mo)
ROSY-S
NCT07691970
P3RecruitingSystemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus10722032-12-30
EvoPAR-PR02
NCT06952803
P3RecruitingProstate Cancer7002033-03-31